CF PHARMTECH (02652) has announced the formal signing of a strategic cooperation agreement with JD Health International Inc. (JD HEALTH) on March 20, 2026. Under this agreement, JD HEALTH will serve as the exclusive online launch partner for several of CF PHARMTECH's key new respiratory and nasal products over the next three years.
Key aspects of the collaboration include: (i) JD HEALTH will leverage its online platform and supply chain capabilities to support the initial online sales and patient services for the new products; (ii) JD HEALTH will utilize its prescription fulfillment and patient management expertise to help enhance the commercialization efficiency of the new products; and (iii) both parties will explore internet-based healthcare models for chronic disease management.
This partnership aims to combine the respective strengths of both companies in innovative drug development and digital healthcare supply chains to accelerate the widespread adoption of high-quality respiratory treatments. The goal is to provide patients with more convenient and standardized medication and chronic disease management services.
CF PHARMTECH has long focused on the research, development, and manufacturing of respiratory and nasal treatments. Supported by its globally competitive technology platform in inhalation formulations, the company continues to advance the development and upgrading of innovative drugs. It has established a product pipeline covering conditions such as allergic rhinitis, chronic sinusitis, asthma, and chronic obstructive pulmonary disease, forming a comprehensive management system that includes both single and compound medications for patients of all ages and disease stages.
The company utilizes inhalation as a delivery method for small molecule and small nucleic acid drugs, exploring improved efficacy and safety balances through cellular and genetic mechanisms. This marks a key transition from complex formulations to pioneering innovative drugs. This approach not only expands treatment areas to severe diseases with significant unmet clinical needs globally, such as respiratory and central nervous system disorders, but also optimizes immune regulation through localized administration strategies. It establishes a synergistic innovation pathway of "localized inhalation delivery + cell-targeted delivery + gene/protein regulation."
Given the large patient base and long-term management requirements for these diseases in China, the board of directors believes that entering into this strategic cooperation agreement aligns with the overall interests of the company and its shareholders. The partnership is expected to enhance patient accessibility to the company's products and improve the commercialization efficiency of new offerings.